Clinical trial · Interventional
Dose-escalation by Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Non Small Cell Lung Cancer
Dose-escalation by Hypofractionated Stereotactic Radiotherapy Simultaneous Integrated Boost IMRT for Brain Metastases in Non Small Cell Lung Cancer：A Phase I Study
NCT05588206CI-TRIAL-00061573unknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of this trial is to assess the safety and feasibility of delivering SBRT to patients with limited BMs (less than 10 lesions of lung cancer) by establishing the maximally tolerated dose (MTD) of SABR in 5 fractions.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Metastases | — | UNRESOLVED | — |
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Stage IV Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hypofractionated Stereotactic Radiotherap | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Hypofractionated Stereotactic Radiotherapy for Brain Metastases
- interventionNames
- Radiation: Hypofractionated Stereotactic Radiotherap
Primary outcomes (1)
- measure
- MTD
- timeFrame
- 1 years
- description
- maximum tolerated dose
Secondary outcomes (3)
- measure
- ARE
- timeFrame
- 2 years
- description
- adverse radiation effect
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histology confirmed that it was non-small cell lung cancer * 1 to 10 brain metastases detected by magnetic resonance imaging (MRI) * A life expectancy of \>3 months according to the DS GPA. * KPS ≥70 * Control of the primary lesions (thorax) at the time of SBRT * 2cm\<Tumor size ≤ 4 cm * Age of 18-75 years old * Patients must be able to undergo contrast enhanced MRI for planning * Adequate bone marrow and organ function Exclusion Criteria: * other malignant tumors * Prior surgery to brain metastasis * Prior brain radiotherapy * Non-small cell lung cancer with more than 10 brain metastases detected by MRI * Contraindication to receiving radiotherapy.
References
Publications (0)
Data not yet available
No reference posted for this study.